Characterization of C1q-binding IgG complexes in systemic lupus erythematosus

https://doi.org/10.1016/0090-1229(84)90011-4Get rights and content

Abstract

The molecular size of C1q-binding immunoglobulin (Ig) G complexes in systemic lupus erythematosus (SLE) sera was studied by gel filtration using C1q solid-phase radioimmunoassay (C1q SPRIA). All 15 SLE sera tested contained predominantly small-sized IgG complexes, cofractionating with monomeric IgG. In contrast to heat-aggregated IgG, these small-sized IgG complexes retained C1q-binding activity even after pepsin digestion, exposure to low pH, or reduction and alkylation, suggesting that the F(ab′)2 region is involved in C1q-binding activity of these complexes. To see whether anti-C1q antibodies or small antigen-IgG complexes, which bind to C1q via their antigens, are responsible for C1q-binding activity via the F(ab′)2 region, the pepsin-digested Ig fractions of SLE sera were fractionated at high salt. C1q-binding activity in the fractions corresponding to the F(ab′)2 region increased 2.5- to 3.9-fold at high salt. These results suggest that the C1q-binding, small-sized IgG complexes may be comprised mostly of anti-C1q antibodies and that some of the antibodies, which are dissociated with their antigens at high salt, might be cross-reactive with C1q.

References (39)

  • R.R. Porter et al.

    Advan. Protein Chem.

    (1979)
  • C.R. Zeiss et al.

    Amer. J. Med.

    (1980)
  • R.J. Levinsky et al.

    Lancet

    (1977)
  • C.L. Anderson et al.

    J. Clin. Invest.

    (1980)
  • S. Aotsuka et al.

    J. Immunol. Methods

    (1979)
  • A.C. Ghose et al.

    Arch. Biochem. Biophys.

    (1971)
  • C.R. Sledge et al.

    J. Biol. Chem.

    (1973)
  • J.L. Roberts et al.

    Clin. Immunol. Immunopathol.

    (1981)
  • L.A. Aarden et al.

    J. Immunol. Methods

    (1976)
  • D. Koffler et al.

    J. Exp. Med.

    (1971)
  • D. Koffler et al.

    Amer. J. Pathol.

    (1974)
  • A.N. Theofilopoulos et al.

    J. Clin. Invest.

    (1976)
  • J.M. Kehoe et al.

    Nature (London)

    (1969)
  • M. Colomb et al.

    Biochem. J.

    (1975)
  • V. Agnello et al.

    J. Exp. Med.

    (1971)
  • R.J. Marder et al.

    J. Immunol.

    (1978)
  • P.O. Cano et al.

    Clin. Exp. Immunol.

    (1977)
  • A.B. Pereira et al.

    J. Immunol.

    (1980)
  • A.S. Cohen et al.

    Bull. Rheum. Dis.

    (1971)
  • Cited by (90)

    • C1q, antibodies and anti-C1q autoantibodies

      2015, Molecular Immunology
      Citation Excerpt :

      By using high-salt buffers it was possible to discriminate between IC binding and binding of these monomeric anti-C1q autoantibodies (Kohro-Kawata et al., 2002). These anti-C1q autoantibodies target only ligand bound, solid-phase, C1q and not fluid-phase C1q (Agnello et al., 1971; Uwatoko et al., 1984) (Fig. 2). The team of Prof. Daha played an important role in highlighting the importance of anti-C1q in routine clinical diagnostics (Coremans et al., 1992; Siegert et al., 1992; Trouw et al., 2004a).

    • Autoantibodies to C1q

      2014, Autoantibodies, Third Edition
    • Autoantibodies to C1q

      2013, Autoantibodies: Third Edition
    • Anti-C1q antibodies and systemic lupus erythematosus in the Tunisian population

      2013, Pathologie Biologie
      Citation Excerpt :

      However, soluble antigens such as complement components are also targeted [2]. The classical pathway of complement is activated by the binding of C1q to complexed immunoglobulins or C-reactive protein and it was demonstrated that antibodies against C1q are present during SLE [3,4]. The presence of anti-C1q antibodies is correlated with reduced C1q levels and associated with more severe illness and nephritis in patients with SLE [5,6].

    View all citing articles on Scopus

    Supported in part by a grant for Autoimmune Diseases from the Ministry of Health and Welfare, Japan.

    View full text